Coronary artery bypass grafting on the beating heart: surgical revascularization for the next decade?
This review considers whether coronary artery bypass grafting (CABG) performed on the beating heart (off-pump or OPCAB) will supersede conventional CABG utilizing cardiopulmonary bypass (CPB) and cardioplegic arrest as the accepted gold standard. Randomized controlled trials, case-matched reports and observational studies have demonstrated lower morbidity in off-pump compared to conventional on-pump CABG with equivalent mid-term outcome at a significantly lower cost. Patients referred for surgical revascularization are increasingly elderly with more co-morbid medical conditions and elimination of CPB-related morbidity in these groups is associated with the most pronounced improvements in outcome, at least in observational studies. Long-term outcome, and in particular, long-term graft patency following OPCAB has not yet been reported. A barrier to the more widespread acceptance of OPCAB is the poor provision for training in off-pump techniques although structured cardiothoracic training that includes OPCAB surgery has been shown to be both possible and safe for patients. The evidence available to date therefore strongly supports the assertion that OPCAB may become the new gold standard in surgical revascularization. Whether it will ultimately replace conventional CABG, however, is dependent on the results of long-term patency studies and the wider development of adequate training programmes.
Murphy
Gavin J
GJ
Department of Cardiac Surgery, Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol BS2 8HW, UK.
Ascione
Raimondo
R
Angelini
Gianni D
GD
D009202:Cardiomyopathies / Q000209:etiology; D047549:Coronary Artery Bypass, Off-Pump / Q000379:methods* / Q000639:trends; D003327:Coronary Disease / Q000601:surgery*; D003328:Coronary Thrombosis / Q000209:etiology; D016207:Cytokines / Q000378:metabolism; D005544:Forecasting; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology; D009422:Nervous System Diseases / Q000209:etiology; D009504:Neutrophils / Q000473:pathology; D010447:Peptide Hydrolases / Q000378:metabolism; D011183:Postoperative Complications / Q000517:prevention & control; D016896:Treatment Outcome
D016207:Cytokines; D010447:Peptide Hydrolases